Radiation Therapy News and Research RSS Feed - Radiation Therapy News and Research

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.
Conventional proton radiotherapy to fight against cancer

Conventional proton radiotherapy to fight against cancer

The future face of modern-day anti-cancer therapy based on charged particles like protons could potentially involve using laser accelerators. However, these facilities will need to be reduced in terms of both size and cost compared to conventional ones. [More]
New guidelines aim to improve delivery of prostate cancer survivorship care

New guidelines aim to improve delivery of prostate cancer survivorship care

New American Cancer Society Prostate Cancer Survivorship Care guidelines released today outline posttreatment clinical follow-up care for the myriad of long-term and late effects an estimated 2.8 million prostate cancer survivors in the United States may face. [More]
Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. [More]
Survival rates for African-Americans with head and neck cancer not improved in the last 40 years

Survival rates for African-Americans with head and neck cancer not improved in the last 40 years

The national survival rates for African-Americans diagnosed with head and neck cancer have not improved in the last 40 years despite advances in the treatment and management of the disease, University of Missouri School of Medicine researchers have found in a new study. [More]
ASTRO issues new Model Policy for proton beam therapy

ASTRO issues new Model Policy for proton beam therapy

The American Society for Radiation Oncology (ASTRO) has issued a new Model Policy for proton beam therapy (PBT) that details which cancer diagnoses meet ASTRO's evidence-based standards and should be covered by private insurers and Medicare. [More]
Congress supports full Medicare coverage of lung cancer screening for seniors

Congress supports full Medicare coverage of lung cancer screening for seniors

A large number of United States Senators and Representatives are taking the lead to support full Medicare coverage of low-dose computed tomography (LDCT) screening for seniors at high risk for lung cancer. [More]
Elekta and Philips partner to develop integrated MRI guided radiation therapy system

Elekta and Philips partner to develop integrated MRI guided radiation therapy system

Elekta and Royal Philips announced today that The Institute of Cancer Research, London, a world-leading cancer research institution, working with its clinical partner The Royal Marsden NHS Foundation Trust, will join the Elekta MR Linac Research Consortium, a group with a mission to develop an integrated magnetic resonance imaging (MRI) guided radiation therapy system. [More]
AMS agrees to sell Gamma Knife and radiation therapy services business in Turkey to Euromedic

AMS agrees to sell Gamma Knife and radiation therapy services business in Turkey to Euromedic

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into an agreement to sell its Gamma Knife and radiation therapy services business in Turkey to Euromedic Cancer Treatment Centers BV. [More]
Immune system-boosting therapy slows recurrence of glioblastoma multiforme

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

A multicenter team of investigators, led by researchers from the Cedars-Sinai Department of Neurosurgery, the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Dana-Farber Cancer Institute in Boston, have found in a Phase II clinical trial that an immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor. [More]
New cancer panel holds promise in detection of previously undetected viral, cancer mutations

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral and cancer mutations are to be reported in a poster presentation titled "Detection of novel HPV mutations and chromosomal number imbalance (CNI) in oropharyngeal and laryngeal cancer using next-generation sequencing (NGS)" (Abstract #6072) at the American Society of Clinical Oncology Annual Meeting (ASCO 2014) being held from May 30 through June 3, 2014 in Chicago. [More]
ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago. [More]
Men who receive radiation therapy for prostate cancer more likely to develop rectal cancer

Men who receive radiation therapy for prostate cancer more likely to develop rectal cancer

Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan Comprehensive Cancer Center. [More]
Researchers uncover previously unidentified genes responsible for keloid scarring

Researchers uncover previously unidentified genes responsible for keloid scarring

Researchers at Henry Ford Hospital in Detroit have uncovered previously unidentified genes that may be responsible for keloid scarring, a discovery that could unlock the mystery of keloid development and provide insight for more effective treatment. [More]
Study suggests proton therapy may be effective, less toxic treatment option for head and neck cancer

Study suggests proton therapy may be effective, less toxic treatment option for head and neck cancer

In a small study, researchers from The University of Texas MD Anderson Cancer Center found that 93 percent of head and neck cancer patients treated with multi-field optimization intensity modulated proton therapy (MFO-IMPT) were cancer-free 28 months after treatment. [More]
Dieting may decrease chances for metastases in triple negative breast cancers

Dieting may decrease chances for metastases in triple negative breast cancers

Calorie restriction, a kind of dieting in which food intake is decreased by a certain percentage, has been touted as way to help people live longer. [More]
Double mastectomies are unnecessary in women with breast cancer, says study

Double mastectomies are unnecessary in women with breast cancer, says study

About 70 percent of women who have both breasts removed following a breast cancer diagnosis do so despite a very low risk of facing cancer in the healthy breast, new research from the University of Michigan Comprehensive Cancer Center finds [More]
Norris Cotton Cancer Center receives 3 year term of accreditation from ACR

Norris Cotton Cancer Center receives 3 year term of accreditation from ACR

The American College of Radiology (ACR) has awarded a three-year term of accreditation to Norris Cotton Cancer Center's (NCCC) Radiation Oncology department after a complete review and on-site surveys of its professional and technical practices and facilities in Lebanon, New Hampshire and St. Johnsbury, Vermont. [More]
Low risk prostate cancer not always low risk

Low risk prostate cancer not always low risk

More and more men who believe they have low-risk prostate cancers are opting for active surveillance, forgoing treatment and monitoring the cancer closely with prostate-specific antigen (PSA) tests, digital rectal exams and ultrasounds at regular intervals to see if their tumors are growing. Nearly 400 men are now enrolled in the UCLA Active Surveillance program, the largest in Southern California. [More]

University of Chicago receives $3.9M award to serve as Lead Academic Participating Site for NCTN

A team from the University of Chicago Medicine Comprehensive Cancer Center has received a five-year, $3.9-million award from the National Cancer Institute to serve as a Lead Academic Participating Site for the newly created National Clinical Trials Network (NCTN). [More]
Treating older men with early-stage prostate cancer does not help live longer

Treating older men with early-stage prostate cancer does not help live longer

Treating older men with early-stage prostate cancer who also have other serious underlying health problems with aggressive therapies such as surgery or radiation therapy does not help them live longer and, in fact, can be detrimental, according to a study by UCLA researchers. [More]